XML 49 R25.htm IDEA: XBRL DOCUMENT
v3.20.2

Fair Value Measurements (Tables) | 6 Months Ended
--- | ---
Jun. 28, 2020
Fair Value Disclosures [Abstract] |
Summary of Derivative Activity | The following table is a summary of the activity related to derivatives and hedges for the fiscal second quarters ended in 2020 and 2019, net of tax:
| June 28, 2020 |  |  |  |  | June 30, 2019 |  |  |  |
(Dollars in Millions) | Sales | Cost of Products Sold | R&D Expense | Interest (Income) Expense | Other (Income) Expense | Sales | Cost of Products Sold | R&D Expense | Interest (Income) Expense | Other (Income) Expense
The effects of fair value, net investment and cash flow hedging: |  |  |  |  |  |  |  |  |  |
Gain (Loss) on net investment hedging relationship: |  |  |  |  |  |  |  |  |  |
Cross currency interest rate swaps contracts: |  |  |  |  |  |  |  |  |  |
Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing | — |  | — |  | — |  | 39 |  | — |  | — |  | — |  | — |  | 39 |  | — |
Amount of gain or (loss) recognized in AOCI | — |  | — |  | — |  | 39 |  | — |  | — |  | — |  | — |  | 39 |  | — |
Gain (Loss) on cash flow hedging relationship: |  |  |  |  |  |  |  |  |  |
Forward foreign exchange contracts: |  |  |  |  |  |  |  |  |  |
Amount of gain or (loss) reclassified from AOCI into income | (2) |  | (62) |  | 2 |  | — |  | — |  | (14) |  | (101) |  | 36 |  | — |  | 2 |
Amount of gain or (loss) recognized in AOCI | (2) |  | (128) |  | (10) |  | — |  | 22 |  | — |  | (50) |  | 18 |  | — |  | (3) |
Cross currency interest rate swaps contracts: |  |  |  |  |  |  |  |  |  |
Amount of gain or (loss) reclassified from AOCI into income | — |  | — |  | — |  | 83 |  | — |  | — |  |  | — |  | 64 |  | — |
Amount of gain or (loss) recognized in AOCI | $ | — |  | — |  | — |  | 100 |  | — |  | — |  | — |  | — |  | 82 |  | — |
The following table is a summary of the activity related to derivatives and hedges for the fiscal six months ended in 2020 and 2019, net of tax:
| June 28, 2020 |  |  |  |  | June 30, 2019 |  |  |  |
(Dollars in Millions) | Sales | Cost of Products Sold | R&D Expense | Interest (Income) Expense | Other (Income) Expense | Sales | Cost of Products Sold | R&D Expense | Interest (Income) Expense | Other (Income) Expense
The effects of fair value, net investment and cash flow hedging: |  |  |  |  |  |  |  |  |  |
Gain (Loss) on net investment hedging relationship: |  |  |  |  |  |  |  |  |  |
Cross currency interest rate swaps contracts: |  |  |  |  |  |  |  |  |  |
Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing | — |  | — |  | — |  | 79 |  | — |  | — |  | — |  | — |  | 78 |  | — |
Amount of gain or (loss) recognized in AOCI | — |  | — |  | — |  | 79 |  | — |  | — |  | — |  | — |  | 78 |  | — |
Gain (Loss) on cash flow hedging relationship: |  |  |  |  |  |  |  |  |  |
Forward foreign exchange contracts: |  |  |  |  |  |  |  |  |  |
Amount of gain or (loss) reclassified from AOCI into income | 7 |  | (235) |  | (108) |  | — |  | (2) |  | (35) |  | (136) |  | (103) |  | — |  | 8 |
Amount of gain or (loss) recognized in AOCI | 9 |  | 174 |  | (120) |  | — |  | (14) |  | (6) |  | (346) |  | (92) |  | — |  | 10 |
Cross currency interest rate swaps contracts: |  |  |  |  |  |  |  |  |  |
Amount of gain or (loss) reclassified from AOCI into income | — |  | — |  | — |  | 181 |  | — |  | — |  | — |  | — |  | 118 |  | — |
Amount of gain or (loss) recognized in AOCI | $ | — |  | — |  | — |  | 725 |  | — |  | — |  | — |  | — |  | 140 |  | — |
The following table is the effect of net investment hedges for the fiscal second quarters ended in 2020 and 2019
|  | Gain/(Loss) Recognized In Accumulated OCI |  |  |  | Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income |  | Gain/(Loss) Reclassified From Accumulated OCI Into Income |  |
(Dollars in Millions) |  | June 28, 2020 |  | June 30, 2019 |  |  |  | June 28, 2020 |  | June 30, 2019
Debt |  | $ | (95) |  |  | (57) |  |  | Interest (income) expense |  | — |  |  | — |
Cross Currency interest rate swaps |  | $ | (186) |  |  | (57) |  |  | Interest (income) expense |  | — |  |  | — |
The following table is the effect of net investment hedges for the fiscal six months ended in 2020 and 2019
|  | Gain/(Loss) Recognized In Accumulated OCI |  |  |  | Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income |  | Gain/(Loss) Reclassified From Accumulated OCI Into Income |  |
(Dollars in Millions) |  | June 28, 2020 |  | June 30, 2019 |  |  |  | June 28, 2020 |  | June 30, 2019
Debt |  | $ | (48) |  |  | 14 |  |  | Interest (income) expense |  | — |  |  | — |
Cross Currency interest rate swaps |  | $ | 641 |  |  | 313 |  |  | Interest (income) expense |  | — |  |  | — |
Schedule of Derivatives Recorded in Consolidated Balance Sheet |
Schedule of Effect of Derivatives not Designated as Hedging Instruments |
|  |  |  | Gain/(Loss) Recognized In Income on Derivative |  |  | Gain/(Loss) Recognized In Income on Derivative |  |  |
(Dollars in Millions) |  | Location of Gain /(Loss) Recognized in Income on Derivative |  | Fiscal Second Quarter Ended |  |  | Fiscal Six Months Ended |  |  |
Derivatives Not Designated as Hedging Instruments |  |  |  | June 28, 2020 |  | June 30, 2019 | June 28, 2020 |  | June 30, 2019 |
Foreign Exchange Contracts |  | Other (income) expense |  | $ | (24) |  |  | (50) |  | 65 |  |  | (88) |  |
Summary of Activity Related to Equity Investments | The following table is a summary of the activity related to equity investments:
(Dollars in Millions) |  | December 29, 2019 |  |  |  |  |  | June 28, 2020 |  |
|  | Carrying Value |  | Changes in Fair Value Reflected in Net Income (1) |  | Sales/ Purchases/Other (2) |  | Carrying Value |  | Non Current Other Assets
Equity Investments with readily determinable value |  | $ | 1,148 |  |  | 196 |  |  | 144 |  |  | 1,488 |  |  | 1,488 |
Equity Investments without readily determinable value |  | $ | 712 |  |  | (28) |  |  | 28 |  |  | 712 |  |  | 712 |
(1) Recorded in Other Income/Expense (2) Other includes impact of currency
Financial Assets and Liabilities at Fair Value | The Company’s significant financial assets and liabilities measured at fair value as of June 28, 2020 and December 29, 2019 were as follows:
|  | June 28, 2020 |  |  |  |  |  |  |  | December 29, 2019
(Dollars in Millions) |  | Level 1 |  | Level 2 |  | Level 3 |  | Total |  | Total(1)
Derivatives designated as hedging instruments: |  |  |  |  |  |  |  |  |  |
Assets: |  |  |  |  |  |  |  |  |  |
Forward foreign exchange contracts |  | $ | — |  |  | 395 |  |  | — |  |  | 395 |  |  | 209 |
Interest rate contracts (2)(3) |  | — |  |  | 1,126 |  |  | — |  |  | 1,126 |  |  | 693 |
Total |  | — |  |  | 1,521 |  |  | — |  |  | 1,521 |  |  | 902 |
Liabilities: |  |  |  |  |  |  |  |  |  |
Forward foreign exchange contracts |  | — |  |  | 260 |  |  | — |  |  | 260 |  |  | 426 |
Interest rate contracts (3) |  | — |  |  | 251 |  |  | — |  |  | 251 |  |  | 193 |
Total |  | — |  |  | 511 |  |  | — |  |  | 511 |  |  | 619 |
Derivatives not designated as hedging instruments: |  |  |  |  |  |  |  |  |  |
Assets: |  |  |  |  |  |  |  |  |  |
Forward foreign exchange contracts |  | — |  |  | 38 |  |  | — |  |  | 38 |  |  | 23 |
Liabilities: |  |  |  |  |  |  |  |  |  |
Forward foreign exchange contracts |  | — |  |  | 47 |  |  | — |  |  | 47 |  |  | 33 |
Other Investments: |  |  |  |  |  |  |  |  |  |
Equity investments (4) |  | 1,488 |  |  | — |  |  | — |  |  | 1,488 |  |  | 1,148 |
Debt securities(5) |  | $ | — |  |  | 10,047 |  |  | — |  |  | 10,047 |  |  | 4,368 |
Other Liabilities |  |  |  |  |  |  |  |  |  |
Contingent consideration (6) |  |  |  |  |  | 796 |  |  | 796 |  |  | 1,715 |
Gross to Net Derivative Reconciliation |  | June 28, 2020 |  | December 29, 2019
(Dollars in Millions) |  |  |  |
Total Gross Assets |  | $ | 1,559 |  |  | 925 |
Credit Support Agreement (CSA) |  | (1,437) |  |  | (841) |
Total Net Asset |  | 122 |  |  | 84 |
Total Gross Liabilities |  | 558 |  |  | 652 |
Credit Support Agreement (CSA) |  | (510) |  |  | (586) |
Total Net Liabilities |  | $ | 48 |  |  | 66 |
Summarized information about changes in liabilities for contingent consideration is as follows:
|  | June 28, 2020 |  | June 30, 2019
(Dollars in Millions) |  |  |  |
Beginning Balance |  | $ | 1,715 |  |  | $ | 397 |
Changes in estimated fair value (7) |  | (938) |  |  | 35 |
Additions |  | 106 |  |  | 1,133 |
Payments |  | (87) |  |  | (3) |
Ending Balance |  | $ | 796 |  |  | $ | 1,562 |
(1)December 30, 2019 assets and liabilities are all classified as Level 2 with the exception of equity investments of $1,148 million, which are classified as Level 1 and contingent consideration of $1,715 million, classified as Level 3. (2)Includes $1 million of non-current other assets as of December 29, 2019. (3) Includes cross currency interest rate swaps and interest rate swaps. (4) Classified as non-current other assets. (5) Classified within cash equivalents and current marketable securities. (6) Includes $793 million and $1,631 million (primarily related to Auris Health), classified as non-current other liabilities as of June 28, 2020 and December 29, 2019, respectively. Includes $3 million and $84 million classified as current liabilities as of June 28, 2020 and December 29, 2019, respectively. (7) Ongoing fair value adjustment amounts are primarily recorded in Research and Development expense. During the fiscal first quarter of 2020, the Company recorded a contingent consideration reversal of $983 million related to the timing of certain developmental milestones associated with the Auris Health acquisition. The one-time reversal of the contingent consideration was recorded in Other income and expense. As of June 28, 2020, the estimated fair value of the remaining contingent consideration is $169 million. For additional details see Note 10 t o the Consolidated Financial Statements.
Marketable Securities | The Company's cash, cash equivalents and current marketable securities as of June 28, 2020 comprised:
(Dollars in Millions) | Carrying Amount |  | Unrecognized Gain |  | Unrecognized Loss |  | Estimated Fair Value |  | Cash & Cash Equivalents |  | Current Marketable Securities
Cash | $ | 2,215 |  |  | — |  |  | — |  |  | 2,215 |  |  | 2,215 |  |  |
Non-U.S. sovereign securities(1) | 655 |  |  | — |  |  | — |  |  | 655 |  |  | 225 |  |  | 430 |
U.S. reverse repurchase agreements | 2,372 |  |  | — |  |  | — |  |  | 2,372 |  |  | 2,372 |  |  | — |
Other reverse repurchase agreements | 460 |  |  | — |  |  | — |  |  | 460 |  |  | 460 |  |  |
Corporate debt securities(1) | 1,279 |  |  | — |  |  | — |  |  | 1,279 |  |  | 301 |  |  | 978 |
Money market funds | 1,528 |  |  | — |  |  | — |  |  | 1,528 |  |  | 1,528 |  |  |
Time deposits(1) | 579 |  |  | — |  |  | — |  |  | 579 |  |  | 579 |  |  |
Subtotal | 9,088 |  |  | — |  |  | — |  |  | 9,088 |  |  | 7,680 |  |  | 1,408 |
|  |  | Unrealized Gain |  | Unrealized Loss |  |  |  |  |  |
U.S. Gov't securities | 9,786 |  |  | — |  |  | — |  |  | 9,786 |  |  | 3,480 |  |  | 6,306 |
Other sovereign securities | 5 |  |  | — |  |  | — |  |  | 5 |  |  | — |  |  | 5 |
Corporate debt securities | 255 |  |  | 1 |  |  | — |  |  | 256 |  |  | 14 |  |  | 242 |
Subtotal available for sale debt(2) | $ | 10,046 |  |  | 1 |  |  | — |  |  | 10,047 |  |  | 3,494 |  |  | 6,553 |
Total cash, cash equivalents and current marketable securities | $ | 19,134 |  |  | 1 |  |  | — |  |  | 19,135 |  |  | 11,174 |  |  | 7,961 |
(1) Held to maturity investments are reported at amortized cost and gains or losses are reported in earnings. (2) Available for sale debt securities are reported at fair value with unrealized gains and losses reported net of taxes in other comprehensive income.
Schedule of Available for Sale Securities Maturities | The contractual maturities of the available for sale securities as of June 28, 2020 are as follows:
(Dollars in Millions) |  | Cost Basis |  | Fair Value
Due within one year |  | $ | 10,023 |  |  | 10,024 |
Due after one year through five years |  | 23 |  |  | 23 |
Due after five years through ten years |  | — |  |  | — |
Total debt securities |  | $ | 10,046 |  |  | 10,047 |
Financial Liabilities not Measured at Fair Value | Financial Instruments not measured at Fair Value: The following financial liabilities are held at carrying amount on the consolidated balance sheet as of June 28, 2020:
(Dollars in Millions) |  | Carrying Amount |  | Estimated Fair Value
Financial Liabilities |  |  |  |
Current Debt |  | $ | 5,332 |  |  | 5,388 |
Non-Current Debt |  |  |  |
2.45% Notes due 2021 |  | 350 |  |  | 360 |
0.250% Notes due 2022 (1B Euro 1.1217) |  | 1,121 |  |  | 1,131 |
2.25% Notes due 2022 |  | 998 |  |  | 1,029 |
6.73% Debentures due 2023 |  | 250 |  |  | 302 |
3.375% Notes due 2023 |  | 803 |  |  | 891 |
2.05% Notes due 2023 |  | 499 |  |  | 523 |
0.650% Notes due 2024 (750MM Euro 1.1217) |  | 839 |  |  | 864 |
5.50% Notes due 2024 (500 MM GBP 1.2431) |  | 618 |  |  | 749 |
2.625% Notes due 2025 |  | 748 |  |  | 813 |
2.45% Notes due 2026 |  | 1,993 |  |  | 2,179 |
2.95% Notes due 2027 |  | 997 |  |  | 1,111 |
2.90% Notes due 2028 |  | 1,494 |  |  | 1,681 |
1.150% Notes due 2028 (750MM Euro 1.1217) |  | 835 |  |  | 917 |
6.95% Notes due 2029 |  | 297 |  |  | 435 |
4.95% Debentures due 2033 |  | 498 |  |  | 689 |
4.375% Notes due 2033 |  | 856 |  |  | 1,127 |
1.650% Notes due 2035 (1.5B Euro 1.1217) |  | 1,667 |  |  | 1,974 |
3.55% Notes due 2036 |  | 989 |  |  | 1,170 |
5.95% Notes due 2037 |  | 992 |  |  | 1,531 |
3.625% Notes due 2037 |  | 1,487 |  |  | 1,791 |
3.40% Notes due 2038 |  | 991 |  |  | 1,168 |
5.85% Debentures due 2038 |  | 696 |  |  | 1,060 |
4.50% Debentures due 2040 |  | 539 |  |  | 736 |
4.85% Notes due 2041 |  | 297 |  |  | 420 |
4.50% Notes due 2043 |  | 495 |  |  | 685 |
3.70% Notes due 2046 |  | 1,974 |  |  | 2,467 |
3.75% Notes due 2047 |  | 991 |  |  | 1,255 |
3.50% Notes due 2048 |  | 742 |  |  | 923 |
Other |  | 6 |  |  | 10 |
Total Non-Current Debt |  | $ | 25,062 |  |  | 29,991 |

X
- Definition Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 320 -URI http://asc.fasb.org/topic&trid=2196928 + Details
Name: | us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 11 -URI http://asc.fasb.org/extlink&oid=118260190&loc=d3e13467-108611 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258 + Details
Name: | us-gaap_FairValueByBalanceSheetGroupingTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_FairValueDisclosuresAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value. + References No definition available. + Details
Name: | us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the components of cash, cash equivalents, and investments. + References No definition available. + Details
Name: | us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 4E -URI http://asc.fasb.org/extlink&oid=109980867&loc=SL5624181-113959 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 4A -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 4C -URI http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959 + Details
Name: | us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 4B -URI http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959 + Details
Name: | us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of derivative liabilities at fair value. + References No definition available. + Details
Name: | us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of derivative instrument not designated or qualifying as hedging instrument. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 4C -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 4CC -URI http://asc.fasb.org/extlink&oid=109980867&loc=SL109998890-113959 + Details
Name: | us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration